Life Biosciences Initiates Gene Therapy Trial to Rejuvenate Cells in Glaucoma Patients
Life Biosciences, a company based in Boston, Massachusetts, has commenced a groundbreaking clinical trial aimed at rejuvenating aged cells to treat glaucoma, a condition that can lead to blindness. The trial involves a novel gene therapy technique that activates three specific genes to 'partially reprogram' old cells, allowing them to function as if they were young again. This approach is being tested on the optic nerve, which connects the eye to the brain and is typically unable to regenerate. The trial's first participant has already been treated, marking a significant milestone in the field of regenerative medicine. The therapy aims to regenerate neurons in the optic nerve, potentially reversing damage caused by glaucoma. While animal studies have shown promise, there are concerns about the safety of this technique, particularly the risk of inducing cancerous states in cells. 
